engleski

Nonantibiotic therapy of Staphylococcus aureus mastits in cow

Mastitis caused by Staphylococcus aureus is difficult to controle due to deficient penetration of antibiotics and S. aureus' ability to survive outside of PMNs and inactivate the antibiotics. The perspective lies in nonantibiotic therapy. Lysostaphine is a mixture of proteolytic enzymes with antistaphylococcal action from staphylolytical staphylococci. The part of Staphylococcus simulans gene was cloned into E. coli, and with procedures of genetic engineering, into the bovine embrio. In this way, transgenetic cow that secretes lysostaphine directly into milk was produced. Staphylococcus aureus produces adhesive matrix moleculs (MSCRAMMs). Factor of adhesion, fibronectin, applied artificially, binds to MSCRAMMs and blocks S. aureus adhesion to mammary epithelium. Imunization of cows with antimatrix antigen results in inactivation of the bacteria. Ranalexin, a peptide isolated from the skin of american bullfrog, has an inhibitory and antitoxical effect, which makes him important in anticipation of ethiological predomination of MRSA mastitis. Staphyloxantin, antioxidative pigment that protects S. aureus from the reactive oxigen of immune system. Blocators of staphyloxantin production inhibit S. aureus resistence?

Staphylococcus aureus mastitis; dairy cow; nonantibiotic therapy

nije evidentirano